Janux Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the advancement of its novel immunotherapy platforms during a virtual R&D Day webcast. The company is progressing with its clinical candidate, JANX007, a TRACTr targeting prostate-specific membrane antigen (PSMA), currently under investigation in a Phase 1 clinical trial for adult patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, Janux has introduced its second clinical candidate, JANX008, a TRACTr targeting epidermal growth factor receptor (EGFR), being evaluated in a Phase 1 clinical trial for various solid cancers. The company is also advancing CD3-based TRACTr and CD28-based TRACIr programs, including a PSMA-TRACIr for combination use with JANX007, and a TROP2-TRACTr for TROP2+ solid tumors. Furthermore, Janux is developing its first ARM platform program, CD19-ARM, aimed at treating autoimmune diseases, with first-in-human trials anticipated in the first half of 2026. Results from these initiatives will be presented in the future.